Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 7, 2008 - Issue 1
Submit an article Journal homepage
502
Views
11
CrossRef citations to date
0
Altmetric
Reviews

Benefits and risks of using antidepressants in children and adolescents

Daniel Bailly Service hospitalo-universitaire de psychiatrie, Hôpital Sainte-Marguerite, 270 Boulevard de Sainte Marguerite, 13009 Marseille, France +33 491 744 082; +33 491 745 578; [email protected]
, MD
Pages 9-27 | Published online: 02 Jan 2008

Bibliography

  • Zito JM, Safer DJ, Dosreis S, et al. Psychotropic practice patterns for youth: a 10-year perspective. Arch Pediatr Adolesc Med 2003;157(1):17-25
  • Jensen PS, Bhatara VS, Vitiello B, Hoagwood K, Feil M, Burke LB. Psychoactive medication prescribing practices for US children: gaps between research and clinical practice. J Am Acad Child Adolesc Psychiatry 1999;38(5):557-65
  • Murray ML, Thompson M, Santosh PJ, Wong IC. Effects of the Committee on Safety of Medicines advice on antidepressant prescribing to children and adolescents in the UK. Drug Saf 2005;28(12):1151-7
  • Volkers AC, Heerdink ER, Van Dijk L. Antidepressant use and off-label prescribing in children and adolescents in Dutch general practice (2001 – 2005). Pharmacoepidemiol Drug Saf 2007;16(9):1054-62
  • Nemeroff CB, Kalali A, Keller MB, et al. Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Arch Gen Psychiatry 2007;64(4):466-72
  • Institut National De La Sante Et De La Recherche Medicale. Données épidémiologiques. In: Troubles mentaux. Dépistage et prévention chez l'enfant et l'adolescent. Les éditions Inserm, Paris 2002. pp. 3-67
  • Emslie GJ, Rush J, Weinberg WA, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997;54(11):1031-7
  • Emslie GJ, Mayes TL. Mood disorders in children and adolescents: psychopharmacological treatment. Biol Psychiatry 2001;49(12):1082-90
  • Courtney DB. Selective serotonin reuptake inhibitor and venlafaxine use in children and adolescents with major depressive disorder: a systematic review of published randomized controlled trials. Can J Psychiatry 2004;49(8):557-63
  • Jureidini JN, Doecke CJ, Mansfield PR, Haby MM, Menkes DB, Tonkin AL. Efficacy and safety of antidepressants for children and adolescents. BMJ 2004;328(7444):879-83
  • Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004;363(9418):1341-5
  • Bridge JA, Salary CB, Birmaher B, Asare AG, Brent DA. The risks and benefits of antidepressant treatment for youth depression. Ann Med 2005;37(6):404-12
  • Cheung AH, Emslie GJ, Mayes TL. Review of the efficacy and safety of antidepressants in youth depression. J Child Psychol Psychiatry 2005;46(7):735-54
  • Hjalmarsson L, Corcos M, Jeammet P. Indication des inhibiteurs de la recapture de la sérotonine au cours d'un épisode dépressif majeur chez l'enfant et l'adolescent (bénéfices/risques). L'Encéphale 2005;31(3):309-16
  • Andrade C, Bhakta SG, Singh NM. Controversy revisited: selective serotonin reuptake inhibitors in paediatric depression. World J Biol Psychiatry 2006;7(4):251-60
  • Bailly D. Efficacité des antidépresseurs inhibiteurs sélectifs de la recapture de la sérotonine chez l'enfant et l'adolescent. Presse Med 2006;35(9):1293-302
  • Wallace AE, Neily J, Weeks WB, Friedman MJ. A cumulative meta-analysis of selective serotonin reuptake inhibitors in pediatric depression: did unpublished studies influence the efficacy/safety debate? J Child Adolesc Psychopharmacol 2006;16(1-2):37-58
  • Papanikolaou K, Richardson C, Pehlivanidis A, Papadopoulou-Daifoti Z. Efficacy of antidepressants in child and adolescent depression: a meta-analytic study. J Neural Transm 2006;113(3):399-415
  • Emslie GJ, Findling RL, Yeung PP, Kunz NR, Li Y. Venlafaxine ER for the treatment of pediatric subjects with depression: results of two placebo-controlled trials. J Am Acad Child Adolesc Psychiatry 2007;46(4):479-88
  • Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007;297(15):1683-96
  • Wagner KD, Ambrosini P, Rynn M, et al. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. JAMA 2003;290(8):1033-41
  • Mayes TL, Tao R, Rintelmann JW, et al. Do children and adolescents have differential response rates in placebo-controlled trials of fluoxetine? CNS Spectr 2007;12(2):147-54
  • Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Carmody T, Mayes TL. Fluoxetine in child and adolescent depression: acute and maintenance treatment. Depress Anxiety 1998;7(1):32-9
  • Brent DA, Holder D, Kolko D, et al. A clinical psychotherapy trial for adolescent depression comparing cognitive, family, and supportive therapy. Arch Gen Psychiatry 1997;54(9):877-85
  • Mufson L, Weissman MM, Moreau D, Garfinkel R. Efficacy of interpersonal psychotherapy for depressed adolescents. Arch Gen Psychiatry 1999;56(6):573-9
  • Mufson L, Dorta KP, Wickramaratne P, Nomura Y, Olfson M, Weissman MM. A randomized effectiveness trial of interpersonal psychotherapy for depressed adolescents. Arch Gen Psychiatry 2004;61(6):577-84
  • March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. JAMA 2004;292(7):807-20
  • Kennard B, Silva S, Vitiello B, et al. Remission and residual symptoms after short-term treatment in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry 2006;45(12):1404-11
  • Kratochvil C, Emslie G, Silva S, et al. Acute time to response in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry 2006;45(12):1412-18
  • Vitiello B, Rohde P, Silva S, et al. Functioning and quality of life in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry 2006;45(12):1419-26
  • Curry J, Rohde P, Simons A, et al. Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry 2006;45(12):1427-39
  • Geller B, Reising D, Leonard HL, Riddle MA, Walsh BT. Critical review of tricyclic antidepressant use in children and adolescents. J Am Acad Child Adolesc Psychiatry 1999;38(5):513-16
  • Hazell P, O'Connell D, Heathcote D, Robertson J, Henry D. Efficacy of tricyclic drugs in treating child and adolescent depression: a meta-analysis. BMJ 1995;310(6984):897-901
  • Hazell P, O'Connell D, Heathcote D, Henry D. Tricyclic drugs for depression in children and adolescents. Cochrane Database Syst Rev 2002;2:CD002317
  • Conners CK. Methodology of antidepressant drug trials for treating depression in adolescents. J Child Adolesc Psychopharmacol 1992;2(1):11-22
  • Keller MB, Ryan ND, Strober M, et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 2001;40(7):762-72
  • Braconnier A, Le Coent R, Cohen D. Paroxetine versus clomipramine in adolescents with severe major depression: a double-blind, randomized, multicenter trial. J Am Acad Child Adolesc Psychiatry 2003;42(1):22-9
  • Geller DA, Biederman J, Stewart SE, et al. Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder. Am J Psychiatry 2003;160(11):1919-28
  • March JS, Klee BJ, Kremer CM. Treatment benefit and the risk of suicidality in multicenter, randomized, controlled trials of sertraline in children and adolescents. J Child Adolesc Psychopharmacol 2006;16(1-2):91-102
  • Cook EH, Wagner KD, March JS, et al. Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 2001;40(10):1175-81
  • Wagner KD, Cook EH, Chung H, Messig M. Remission status after long-term sertraline treatment of pediatric obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 2003;13(Suppl 1):S53-S60
  • Geller DA, Biederman J, Stewart SE, et al. Impact of comorbidity on treatment response to paroxetine in pediatric obsessive-compulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials? J Child Adolesc Psychopharmacol 2003;13(Suppl 1):S19-S29
  • Yaryura-Tobias JA, Grunes MS, Walz J, Neziroglu F. Parental obsessive-compulsive disorder as a prognostic factor in a year long fluvoxamine treatment in childhood and adolescent obsessive-compulsive disorder. Int Clin Psychopharmacol 2000;15(3):163-8
  • Piacentini J. Cognitive behavioral therapy of childhood OCD. Child Adolesc Psychiatr Clin North Am 1999;8(3):599-616
  • Neziroglu F, Yaryura-Tobias JA, Walz J, McKay D. The effect of fluvoxamine and behavior therapy on children and adolescents with obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 2000;10(4):295-306
  • Pediatric OCD Treatment Study (POTS) team. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA 2004;292(16):1969-76
  • Grados M, Scahill L, Riddle MA. Pharmacotherapy in children and adolescents with obsessive-compulsive disorder. Child Adolesc Psychiatr Clin North Am 1999;8(3):617-34
  • Leonard HL, Swedo SE, Lenane MC, et al. A double-blind desipramine substitution during long-term clomipramine treatment in children and adolescents with obsessive-compulsive disorder. Arch Gen Psychiatry 1991;48(10):922-7
  • Rettew DC, Swedo SE, Leonard HL, Lenane MC, Rapoport JL. Obsessions and compulsions across time in 79 children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 1992;31(6):1050-6
  • Swedo SE, Rapoport JL. Phenomenology and differential diagnosis of obsessive compulsive disorder in children and adolescents. In: Obsessive Compulsive Disorder in Children and Adolescents. Rapoport JL, editor. American Psychiatric Press, Washington DC; 1989. pp. 13-32
  • Birmaher B, Axelson DA, Monk K, et al. Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 2003;42(4):415-23
  • Walkup J, Labellarte M, Riddle MA, et al. Treatment of pediatric anxiety disorders: an open-label extension of the research units on pediatric psychopharmacology anxiety study. J Child Adolesc Psychopharmacol 2002;12(3):175-88
  • James A, Soler A, Weatherall R. Cognitive behavioural therapy for anxiety disorders in children and adolescents. Cochrane Database Syst Rev 2005;4:CD004690
  • In-Albon T, Schneider S. Psychotherapy of childhood anxiety disorders: a meta-analysis. Psychother Psychosom 2007;76(1):15-24
  • Barrickman LL, Noyes R, Kuperman S, Schumacher E, Verda M. Treatment of ADHD with fluoxetine: a preliminary trial. J Am Acad Child Adolesc Psychiatry 1991;30(5):762-7
  • Quintana H, Butterbaugh GJ, Purnell W, Layman AK. Fluoxetine monotherapy in attention-deficit/hyperactivity disorder and comorbid non-bipolar mood disorders in children and adolescents. Child Psychiatry Hum Dev 2007;37(3):241-53
  • Olvera RL, Pliszka SR, Luh J, Tatum R. An open trial of venlafaxine in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. J Child Adolesc Psychopharmacol 1996;6(4):241-50
  • Mukaddes NM, Abali O. Venlafaxine in children and adolescents with attention deficit hyperactivity disorder. Psychiatry Clin Neurosci 2004;58(1):92-5
  • Findling RL, Greenhill LL, McNamara NK, et al. Venlafaxine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2007;17(4):433-46
  • Emslie GJ, Walkup JT, Pliszka SR, Ernst M. Nontricyclic antidepressants: current trends in children and adolescents. J Am Acad Child Adolesc Psychiatry 1999;38(5):517-28
  • Spencer TJ, Biederman J, Wilens TE, Faraone SV. Novel treatments for attention-deficit/hyperactivity disorder in children. J Clin Psychiatry 2002;63(Suppl 12):16-22
  • Bailly D, Vaiva G. Treatment of attention deficit/hyperactivity disorder with monoamine oxidase inhibitors from childhood to adulthood. In: Attention Deficit Hyperactivity Disorder (ADHD) Research. Larimer MP, editor. Nova Science Publishers, Inc., New York 2005. pp. 189-205
  • Akhondzadeh S, Tavakolian R, Davari-Ashtiani R, Arabgol F, Amini H. Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial. Prog Neuropsychopharmacol Biol Psychiatry 2003;27(5):841-5
  • Mohammadi MR, Ghanizadeh A, Alaghband-Rad J, Tehradidoost M, MesgarpouR B, Soori H. Selegiline in comparison with methylphenidate in attention deficit hyperactivity disorder children and adolescents in a double-blind, randomized clinical trial. J Child Adolesc Psychopharmacol 2004;14(3):418-25
  • Rubinstein S, Malone MA, Roberts W, Logan WJ. Placebo-controlled study examining effects of selegiline in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2006;16(4):404-15
  • Barrickman LL, Perry PJ, Allen AJ, et al. Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995;34(5):649-57
  • Donnelly M, Zametkin AJ, Rapoport JL, et al. Treatment of childhood hyperactivity with desipramine: plasma drug concentration, cardiovascular effects, plasma and urinary catecholamine levels, and clinical response. Clin Pharmacol Ther 1986;39(1):72-81
  • Biederman J, Baldessarini RJ, Wright V, Knee D, Harmatz JS. A double-blind placebo controlled study of desipramine in the treatment of ADD. I. Efficacy. J Am Acad Child Adolesc Psychiatry 1989;28(5):777-84
  • Rapoport JL, Quinn PO, Bradbard G, Riddle KD, Brooks E. Imipramine and methylphenidate treatments of hyperactive boys. A double-blind comparison. Arch Gen Psychiatry 1974;30(6):789-93
  • Werry J, Aman MG, Diamond E. Imipramine and methylphenidate in hyperactive children. J Child Psychol Psychiatry 1979;21(1):27-35
  • Gualtieri CT, Evans RW. Motor performance in hyperactive children treated with imipramine. Percept Mot Skills 1988;66(3):763-9
  • Singer HS, Brown J, Quaskey S, Rosenberg LA, Mellits ED, Denckla MB. The treatment of attention-deficit hyperactivity disorder in Tourette's syndrome: a double-blind placebo-controlled study with clonidine and desipramine. Pediatrics 1995;95(1):74-81
  • Spencer T, Biederman J, Coffey B, et al. A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2002;59(7):649-56
  • Quinn PO, Rapoport JL. One-year follow-up of hyperactive boys treated with imipramine or methylphenidate. Am J Psychiatry 1975;132(3):241-45
  • Riddle MA, King RA, Hardin MT, et al. Behavioral side effects of fluoxetine in children and adolescents. J Child Adolesc Psychopharmacol 1991;1(2):193-8
  • King RA, Riddle MA, Chappell PB, et al. Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment. J Am Acad Child Adolesc Psychiatry 1991;30(2):179-86
  • Cole JO, Bodkin JA. Antidepressant drug side effects. J Clin Psychiatry 1990;51(Suppl):21-6
  • Tierney E, Joshi PT, Llinas JF, Rosenberg LA, Riddle MA. Sertraline for major depression in children and adolescents: preliminary clinical experience. J Child Adolesc Psychopharmacol 1995;5(1):13-27
  • Walkup JT. A differential diagnosis of the adverse behavioral effects of fluoxetine. Newsl Am Acad Child Adolesc Psychiatry 1994;25(3):28-30
  • March JS, Biederman J, Wolkow R, et al. Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. JAMA 1998;280(20):1752-6
  • Emslie G, Kratochvil C, Vitiello B, et al. Treatment for Adolescents with Depression Study (TADS): safety results. J Am Acad Child Adolesc Psychiatry 2006;45(12):1440-55
  • Fluvoxamine for the treatment of anxiety disorders in children and adolescents. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group. N Engl J Med 2001;344(17):1279-85
  • Bailly D. Tolérance des antidépresseurs inhibiteurs sélectifs de la recapture de la sérotonine chez l'enfant et l'adolescent. Presse Med 2006;35(10):1507-15
  • Gualtieri CT, Johnson LG. Antidepressant side effects in children and adolescents. J Child Adolesc Psychopharmacol 2006;16(1-2):147-57
  • Zuckerman ML, Vaughan BL, Whitney J, et al. Tolerability of selective serotonin reuptake inhibitors in thirty-nine children under age seven: a retrospective chart review. J Child Adolesc Psychopharmacol 2007;17(2):165-74
  • Wilens TE, Biederman J, Kwon A, et al. A systematic chart review of the nature of psychiatric adverse events in children and adolescents treated with selective serotonin reuptake inhibitors. J Child Adolesc Psychopharmacol 2003;13(2):143-52
  • Wong IC, Besag FM, Santosh PJ, Murray ML. Use of selective serotonin reuptake inhibitors in children and adolescents. Drug Saf 2004;27(13):991-1000
  • Mosholder AD, Willy M. Suicidal adverse events in pediatric randomized, controlled clinical trials of antidepressant drugs are associated with active drug treatment: a meta-analysis. J Child Adolesc Psychopharmacol 2006;16(1-2):25-32
  • Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006;63(3):332-9
  • Wohlfarth TD, Van Zwieten BJ, Lekkerkerker FJ, et al. Antidepressants use in children and adolescents and the risk of suicide. Eur Neuropsychopharmacol 2006;16(2):79-83
  • Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990;147(2):207-10
  • Fergusson D, Doucette S, Glass KC, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ 2005;330(7488):396
  • Aursnes I, Tvete IF, Gaasemyr J, Natvig B. Even more suicide attempts in clinical trials with paroxetine randomised against placebo. BMC Psychiatry 2006;6:55
  • Wagner KD, Berard R, Stein MB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry 2004;61(11):1153-62
  • Geller DA, Wagner KD, Emslie G, et al. Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2004;43(11):1387-96
  • Olfson M, Shaffer D, Marcus SC, Greenberg T. Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry 2003;60(10):978-82
  • Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationship between antidepressant prescription rates and rate of early adolescent suicide. Am J Psychiatry 2006;163(11):1898-904
  • Grunebaum MF, Ellis SP, Li S, Oquendo MA, Mann JJ. Antidepressants and suicide risk in the United States, 1985 – 1999. J Clin Psychiatry 2004;65(11):1456-62
  • Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationship between antidepressant medication use and rate of suicide. Arch Gen Psychiatry 2005;62(2):165-72
  • Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA 2004;292(3):338-43
  • Martinez C, Rietbrock S, Wise L, et al. Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. BMJ 2005;330(7488):389
  • Didham RC, McConnell DW, Blair HJ, Reith DM. Suicide and self-harm following prescription of SSRIs and other antidepressants: confounding by indication. Br J Clin Pharmacol 2005;60(5):519-25
  • Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Tanskanen A, Haukka J. Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Arch Gen Psychiatry 2006;63(12):1358-67
  • Valuck RJ, Libby AM, Sills MR, Giese AA, Allen RR. Antidepressant treatment and risk of suicide attempt by adolescents with major depressive disorder: a propensity-adjusted retrospective cohort study. CNS Drugs 2004;18(15):1119-32
  • Olfson M, Marcus SC, Shaffer D. Antidepressant drug therapy and suicide in severely depressed children and adults: a case-control study. Arch Gen Psychiatry 2006;63(8):865-72
  • Kapur S, Mieczkowski T, Mann JJ. Antidepressant medications and the relative risk of suicide attempt and suicide. JAMA 1992;268(24):3441-5
  • Gibbons RD, Brown CH, Hur K, et al. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 2007;164(9):1356-63
  • Nilsson M, Joliat MJ, Miner CM, Brown EB, Heiligenstein JH. Safety of subchronic treatment with fluoxetine for major depressive disorder in children and adolescents. J Child Adolesc Psychopharmacol 2004;14(3):412-17
  • Warden SJ, Robling AG, Sanders MS, Bliziotes MM, Turner CH. Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth. Endocrinology 2005;146(2):685-93
  • Pine DS. Treating children and adolescents with selective serotonin reuptake inhibitors: how long is appropriate? J Child Adolesc Psychopharmacol 2002;12(3):189-203
  • Landry M, Frasier M, Chen Z, et al. Fluoxetine treatment of prepubescent rats produces a selective functional reduction in the 5-HT2A receptor-mediated stimulation of oxytocin. Synapse 2005;58(2):102-9
  • Ryan ND. Heterocyclic antidepressants in children and adolescents. J Child Adolesc Psychopharmacol 1990;1(1):21-30
  • Preskorn SH, Weller E, Jerkovich G, Hughes CW, Weller R. Depression in children: concentration-dependent CNS toxicity of tricyclic antidepressants. Psychopharmacol Bull 1988;24(1):140-2
  • Leeder JS. Ontogeny of drug-metabolising enzymes and its influence on the pathogenesis of adverse drug reactions in children. Curr Ther Res 2001;62(12):900-12
  • Findling RL, McNamara NK, Stansbrey RJ, et al. The relevance of pharmacokinetic studies in designing efficacy trials in juvenile major depression. J Child Adolesc Psychopharmacol 2006;16(1-2):131-45
  • Leeder JS. Translating pharmacogenetics and pharmacogenomics into drug development for clinical pediatrics and beyond. Drug Discov Today 2004;9(13):567-73
  • Berk M, Dodd S. Are treatment emergent suicidality and decreased response to antidepressants in younger patients due to bipolar disorder being misdiagnosed as unipolar depression? Med Hypotheses 2005;65(1):39-43
  • Apter A, Lipschitz A, Fong R, et al. Evaluation of suicidal thoughts and behaviors in children and adolescents taking paroxetine. J Child Adolesc Psychopharmacol 2006;16(1-2):77-90
  • Bridge JA, Barbe RP, Birmaher B, Kolko DJ, Brent DA. Emergent suicidality in a clinical psychotherapy trial for adolescent depression. Am J Psychiatry 2005;162(11):2173-5
  • Mann JJ, Waternaux C, Haas GL, Malone KM. Toward a clinical model of suicidal behavior in psychiatric patients. Am J Psychiatry 1999;156(2):181-9
  • Mann JJ, Brent DA, Arango V. The neurobiology and genetics of suicide and attempted suicide: a focus on the serotonergic system. Neuropsychopharmacology 2001;24(5):467-77
  • McMahon FJ, Buervenich S, Charney D, et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 2006;78(5):804-14
  • Weisz JR, Jensen-Doss A, Hawley KM. Evidence-based youth psychotherapies versus usual clinical care: a meta-analysis of direct comparisons. Am Psychol 2006;61(7):671-89
  • Harrington R, Whittaker J, Shoebridge P, Campbell F. Systematic review of efficacy of cognitive behaviour therapies in childhood and adolescent depressive disorder. BMJ 1998;316(7144):1559-63
  • Weisz JR, McCarty CA, Valeri SM. Effects of psychotherapy for depression in children and adolescents: a meta-analysis. Psychol Bull 2006;132(1):132-49
  • Nardi DA, Barrett S. Potential effects of antidepressant agents on the growth and development of children and adolescents. J Psychosoc Nurs Ment Health Serv 2005;43(1):22-35
  • Bailly D, Olivier N, Faessel AI. Stress de la période périnatale et troubles émotionnels - aspects biologiques. In: Psychiatrie de l'enfant et de l'adolescent. Bailly D, editor. Doin Editeurs, Paris; 2002. pp. 179-94

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.